Published in Metallomics on July 24, 2015
Genome engineering using the CRISPR-Cas9 system. Nat Protoc (2013) 15.98
Copper is required for oncogenic BRAF signalling and tumorigenesis. Nature (2014) 2.85
Ubiquitination and endocytosis of plasma membrane proteins: role of Nedd4/Rsp5p family of ubiquitin-protein ligases. J Membr Biol (2000) 2.59
Biochemical and genetic analyses of yeast and human high affinity copper transporters suggest a conserved mechanism for copper uptake. J Biol Chem (2002) 2.24
An antimicrobial peptide regulates tumor-associated macrophage trafficking via the chemokine receptor CCR2, a model for tumorigenesis. PLoS One (2010) 2.08
Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs. Mol Pharmacol (2010) 1.99
A novel role for XIAP in copper homeostasis through regulation of MURR1. EMBO J (2003) 1.90
Molecular characterization of a putative Arabidopsis thaliana copper transporter and its yeast homologue. J Biol Chem (1995) 1.86
Affinity gradients drive copper to cellular destinations. Nature (2010) 1.82
Three-dimensional structure of the human copper transporter hCTR1. Proc Natl Acad Sci U S A (2009) 1.79
Nedd4 and Nedd4-2: closely related ubiquitin-protein ligases with distinct physiological functions. Cell Death Differ (2010) 1.77
The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs. Mol Pharmacol (2008) 1.56
C-terminal domain of the membrane copper transporter Ctr1 from Saccharomyces cerevisiae binds four Cu(I) ions as a cuprous-thiolate polynuclear cluster: sub-femtomolar Cu(I) affinity of three proteins involved in copper trafficking. J Am Chem Soc (2004) 1.47
Human copper transporter 2 is localized in late endosomes and lysosomes and facilitates cellular copper uptake. Biochem J (2007) 1.47
Mobilization of intracellular copper stores by the ctr2 vacuolar copper transporter. J Biol Chem (2004) 1.45
Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin. Clin Cancer Res (2009) 1.37
Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth. Mol Cancer Ther (2005) 1.32
O-linked glycosylation at threonine 27 protects the copper transporter hCTR1 from proteolytic cleavage in mammalian cells. J Biol Chem (2007) 1.30
Regulation of copper-dependent endocytosis and vacuolar degradation of the yeast copper transporter, Ctr1p, by the Rsp5 ubiquitin ligase. Traffic (2007) 1.30
Ctr2 is partially localized to the plasma membrane and stimulates copper uptake in COS-7 cells. Biochem J (2008) 1.29
A novel role for copper in Ras/mitogen-activated protein kinase signaling. Mol Cell Biol (2012) 1.24
A structural perspective on copper uptake in eukaryotes. Biometals (2007) 1.20
Copper modulates the degradation of copper chaperone for Cu,Zn superoxide dismutase by the 26 S proteosome. J Biol Chem (2003) 1.19
Ctr1 is an apical copper transporter in mammalian intestinal epithelial cells in vivo that is controlled at the level of protein stability. J Biol Chem (2010) 1.19
Metal transporters that contribute copper to metallochaperones in Saccharomyces cerevisiae. Mol Genet Genomics (2001) 1.18
A C-terminal domain of the membrane copper pump Ctr1 exchanges copper(I) with the copper chaperone Atx1. Chem Commun (Camb) (2002) 1.17
Copper transport activity of yeast Ctr1 is down-regulated via its C terminus in response to excess copper. J Biol Chem (2008) 1.12
Identification of a vacuole-associated metalloreductase and its role in Ctr2-mediated intracellular copper mobilization. J Biol Chem (2007) 1.12
Regulation of the copper chaperone CCS by XIAP-mediated ubiquitination. Mol Cell Biol (2010) 1.03
Copper influx transporter 1 is required for FGF, PDGF and EGF-induced MAPK signaling. Biochem Pharmacol (2012) 1.02
Overcoming platinum resistance through the use of a copper-lowering agent. Mol Cancer Ther (2012) 1.01
Regulation of Cisplatin cytotoxicity by cu influx transporters. Met Based Drugs (2011) 1.00
Ctr1 transports silver into mammalian cells. J Trace Elem Med Biol (2010) 0.99
Ctr2 regulates biogenesis of a cleaved form of mammalian Ctr1 metal transporter lacking the copper- and cisplatin-binding ecto-domain. Proc Natl Acad Sci U S A (2013) 0.96
An all-atom model of the structure of human copper transporter 1. Cell Biochem Biophys (2012) 0.95
Functional characterization of CgCTR2, a putative vacuole copper transporter that is involved in germination and pathogenicity in Colletotrichum gloeosporioides. Eukaryot Cell (2008) 0.89
Copper transporter 2 regulates intracellular copper and sensitivity to cisplatin. Metallomics (2014) 0.88
Rate and regulation of copper transport by human copper transporter 1 (hCTR1). J Biol Chem (2013) 0.86
Characterization of a monoclonal antibody capable of reliably quantifying expression of human Copper Transporter 1 (hCTR1). J Trace Elem Med Biol (2013) 0.80
Molecular modulation of the copper and cisplatin transport function of CTR1 and its interaction with IRS-4. Biochem Pharmacol (2014) 0.79
Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Res (2002) 1.98
Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Mol Cancer Ther (2005) 1.89
Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients. Clin Cancer Res (2003) 1.79
Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Mol Pharmacol (2006) 1.75
The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae. Mol Pharmacol (2002) 1.62
Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit Rev Oncol Hematol (2005) 1.61
Porous silicon nanoparticle photosensitizers for singlet oxygen and their phototoxicity against cancer cells. ACS Nano (2011) 1.61
Intraperitoneal therapy for stage III ovarian cancer: a therapy whose time has come! J Clin Oncol (2002) 1.56
The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs. Mol Pharmacol (2008) 1.56
The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Mol Pharmacol (2004) 1.53
The internalization and degradation of human copper transporter 1 following cisplatin exposure. Cancer Res (2006) 1.51
Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clin Cancer Res (2004) 1.49
Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells. Clin Cancer Res (2004) 1.44
Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B. Mol Pharmacol (2004) 1.41
Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin. Clin Cancer Res (2009) 1.37
Intracellular localization and trafficking of fluorescein-labeled cisplatin in human ovarian carcinoma cells. Clin Cancer Res (2005) 1.30
Transport of cisplatin by the copper efflux transporter ATP7B. Mol Pharmacol (2007) 1.30
DNA polymerase zeta regulates cisplatin cytotoxicity, mutagenicity, and the rate of development of cisplatin resistance. Cancer Res (2004) 1.24
Confocal microscopic analysis of the interaction between cisplatin and the copper transporter ATP7B in human ovarian carcinoma cells. Clin Cancer Res (2004) 1.23
Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1. Clin Cancer Res (2009) 1.22
Diazonamide A and a synthetic structural analog: disruptive effects on mitosis and cellular microtubules and analysis of their interactions with tubulin. Mol Pharmacol (2003) 1.20
Untargeted metabolomics identifies enterobiome metabolites and putative uremic toxins as substrates of organic anion transporter 1 (Oat1). J Proteome Res (2011) 1.18
Effects of the loss of Atox1 on the cellular pharmacology of cisplatin. J Inorg Biochem (2008) 1.16
A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors. Clin Cancer Res (2004) 1.14
Expression of the human copper influx transporter 1 in normal and malignant human tissues. J Histochem Cytochem (2006) 1.12
In vivo time-gated fluorescence imaging with biodegradable luminescent porous silicon nanoparticles. Nat Commun (2013) 1.11
Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system. Clin Cancer Res (2006) 1.10
The copper export pump ATP7B modulates the cellular pharmacology of carboplatin in ovarian carcinoma cells. Mol Pharmacol (2003) 1.10
An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis. J Neurooncol (2002) 1.10
Intra-arterial chemotherapy for head and neck cancer: is there a verdict? Cancer (2010) 1.10
Tight junction proteins claudin-3 and claudin-4 control tumor growth and metastases. Neoplasia (2012) 1.09
DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance. Mol Cancer Ther (2006) 1.09
Regulation of copper transporter 2 expression by copper and cisplatin in human ovarian carcinoma cells. Mol Pharmacol (2010) 1.06
Cross-resistance to cisplatin in cells with acquired resistance to copper. Cancer Chemother Pharmacol (2003) 1.06
The role of copper transporters in the development of resistance to Pt drugs. J Inorg Biochem (2004) 1.03
Identification of genes whose expression is associated with cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol (2006) 1.03
Copper influx transporter 1 is required for FGF, PDGF and EGF-induced MAPK signaling. Biochem Pharmacol (2012) 1.02
Increased levels and defective glycosylation of MRPs in ovarian carcinoma cells resistant to oxaliplatin. Biochem Pharmacol (2009) 1.02
Pharmacokinetics and tissue distribution of PGG-paclitaxel, a novel macromolecular formulation of paclitaxel, in nu/nu mice bearing NCI-460 lung cancer xenografts. Cancer Chemother Pharmacol (2009) 1.01
Copper transporter 2 regulates endocytosis and controls tumor growth and sensitivity to cisplatin in vivo. Mol Pharmacol (2010) 1.00
Regulation of Cisplatin cytotoxicity by cu influx transporters. Met Based Drugs (2011) 1.00
Synthesis, characterization, and biological evaluation of poly(L-γ-glutamyl-glutamine)- paclitaxel nanoconjugate. Int J Nanomedicine (2010) 1.00
DNA polymerase zeta accounts for the reduced cytotoxicity and enhanced mutagenicity of cisplatin in human colon carcinoma cells that have lost DNA mismatch repair. Clin Cancer Res (2006) 0.99
Preclinical efficacy studies of a novel nanoparticle-based formulation of paclitaxel that out-performs Abraxane. Cancer Chemother Pharmacol (2009) 0.99
Identification of substituted pyrimido[5,4-b]indoles as selective Toll-like receptor 4 ligands. J Med Chem (2013) 0.99
Suppression of hREV1 expression reduces the rate at which human ovarian carcinoma cells acquire resistance to cisplatin. Mol Pharmacol (2005) 0.99
Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers. Hum Pathol (2005) 0.98
Human REV1 modulates the cytotoxicity and mutagenicity of cisplatin in human ovarian carcinoma cells. Mol Pharmacol (2006) 0.98
Recombinant CPE fused to tumor necrosis factor targets human ovarian cancer cells expressing the claudin-3 and claudin-4 receptors. Mol Cancer Ther (2009) 0.97
An all-atom model of the structure of human copper transporter 1. Cell Biochem Biophys (2012) 0.95
Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients. Cancer Chemother Pharmacol (2007) 0.95
MAPAS: a tool for predicting membrane-contacting protein surfaces. Nat Methods (2008) 0.94
Regulation of the Epithelial-Mesenchymal Transition by Claudin-3 and Claudin-4. PLoS One (2013) 0.94
cDNA microarray-based identification of genes and pathways associated with oxaliplatin resistance. Cancer Chemother Pharmacol (2004) 0.93
The role of the methionines and histidines in the transmembrane domain of mammalian copper transporter 1 in the cellular accumulation of cisplatin. Mol Pharmacol (2010) 0.93
CD44-targeted microparticles for delivery of cisplatin to peritoneal metastases. Mol Pharm (2010) 0.93
A6 peptide activates CD44 adhesive activity, induces FAK and MEK phosphorylation, and inhibits the migration and metastasis of CD44-expressing cells. Mol Cancer Ther (2011) 0.92
The CXXC motifs in the metal binding domains are required for ATP7B to mediate resistance to cisplatin. J Inorg Biochem (2012) 0.91
The role of the N-terminus of mammalian copper transporter 1 in the cellular accumulation of cisplatin. Biochem Pharmacol (2010) 0.89
Direct recognition of superparamagnetic nanocrystals by macrophage scavenger receptor SR-AI. ACS Nano (2013) 0.89
Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters. Cancer Chemother Pharmacol (2005) 0.89
Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and cisplatin influx transporter CTR1. Mol Pharmacol (2012) 0.88
Acidic hydrolysis of N-Ethoxybenzylimidazoles (NEBIs): potential applications as pH-sensitive linkers for drug delivery. Bioconjug Chem (2007) 0.88
Copper transporter 2 regulates intracellular copper and sensitivity to cisplatin. Metallomics (2014) 0.88
Cisplatin-loaded porous Si microparticles capped by electroless deposition of platinum. Small (2011) 0.87
Characterization of a clinical polymer-drug conjugate using multiscale modeling. Biopolymers (2010) 0.87
Tetramerization domain mutations in KCNA5 affect channel kinetics and cause abnormal trafficking patterns. Am J Physiol Cell Physiol (2009) 0.85
Challenges associated with the targeted delivery of gelonin to claudin-expressing cancer cells with the use of activatable cell penetrating peptides to enhance potency. BMC Cancer (2011) 0.84
Dysregulation of purine nucleotide biosynthesis pathways modulates cisplatin cytotoxicity in Saccharomyces cerevisiae. Mol Pharmacol (2008) 0.83
Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin. Cancer Chemother Pharmacol (2006) 0.83
The role of metal binding and phosphorylation domains in the regulation of cisplatin-induced trafficking of ATP7B. Metallomics (2013) 0.82
Dynamics of soft nanomaterials captured by transmission electron microscopy in liquid water. J Am Chem Soc (2014) 0.81
Elucidation of common pharmacophores from analysis of targeted metabolites transported by the multispecific drug transporter-Organic anion transporter1 (Oat1). Bioorg Med Chem (2011) 0.80
Targeting granzyme B to tumor cells using a yoked human chorionic gonadotropin. Cancer Chemother Pharmacol (2011) 0.80
Sec61β controls sensitivity to platinum-containing chemotherapeutic agents through modulation of the copper-transporting ATPase ATP7A. Mol Pharmacol (2012) 0.80
A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol (2012) 0.79
Tumor platinum concentration following intraperitoneal administration of cisplatin versus carboplatin in an ovarian cancer model. Gynecol Oncol (2009) 0.79
Aggregation properties of a polymeric anticancer therapeutic: a coarse-grained modeling study. J Chem Inf Model (2011) 0.79
NMR and mutagenesis of human copper transporter 1 (hCtr1) show that Cys-189 is required for correct folding and dimerization. Biochim Biophys Acta (2007) 0.78
Neuroprotective effects of the anti-cancer drug sunitinib in models of HIV neurotoxicity suggests potential for the treatment of neurodegenerative disorders. Br J Pharmacol (2014) 0.78
Identification of transdominant-negative genetic suppressor elements derived from hMSH2 that mediate resistance to 6-thioguanine. Mol Pharmacol (2002) 0.77
p75 neurotrophin receptor is a clock gene that regulates oscillatory components of circadian and metabolic networks. J Neurosci (2013) 0.76
Copper transporters and chaperones CTR1, CTR2, ATOX1, and CCS as determinants of cisplatin sensitivity. Metallomics (2016) 0.76
Cellular Delivery of Nanoparticles Revealed with Combined Optical and Isotopic Nanoscopy. ACS Nano (2016) 0.75
Integrin αV control of Cu homeostasis and cisplatin sensitivity. Cell Cycle (2014) 0.75
Coarse-grained modeling study of nonpeptide RGD ligand density and PEG molecular weight on the conformation of poly(γ-glutamyl-glutamate) paclitaxel conjugates. J Mol Model (2011) 0.75
Effects of solution concentration on the physicochemical properties of a polymeric anticancer therapeutic. Mol Pharm (2011) 0.75